UNSPSC 51323006: Levocarnitine propionate

This classification denotes a nutritional supplement with the molecular formula C10H19NO4, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier 0HU2UI27HF. European Medicines Agency schedules levocarnitine propionate in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB26424. The term levocarnitine propionate is a U.S. FDA designation. Most nations, for tariff and trade purposes, schedule levocarnitine propionate under HS 29239000 and SITC 51481.

As of Q4 2014, LEVOCARNITINE PROPIONATE remains US FDA's Preferred Term for this commodity. SMILES: CCC(=O)O[C@H](CC(=O)[O-])C[N+](C)(C)C.

UNSPSC 51323006 Levocarnitine propionate is a Commodity code covering a single pharmaceutical ingredient supplied to state and local health systems, emergency services, and health benefit programs. Recent state and local solicitations show demand for this and related specialty pharmaceuticals through multiple procurement channels: direct emergency medical supply purchases by city fire and rescue services; state health agency requests for information on direct-to-manufacturer prescription fulfillment programs; and multistate cooperative purchasing vehicles aggregating generic and specialty pharmaceutical sourcing across dozens of jurisdictions. Work solicited under this code typically involves supply agreements with firm pricing, guaranteed shelf life and expiration-date management, bulk quantities measured in hundreds to thousands of units per line item, expedited delivery timelines (frequently within ten calendar days), compliance with cGMP and FDA requirements, and submission of Safety Data Sheets and manufacturing documentation.

The issuing bodies span city purchasing departments (Tampa), state health agencies (Texas HHS Commission), and multistate cooperative purchasing alliances (MMCAP). Recent activity centers in Florida and Minnesota, with Texas and multistate reach via MMCAP's cooperative model that extends into Oregon and beyond. Representative opportunities include the City of Tampa's IFB for Advanced Life Support Medications (Solicitation 26P00188, due April 8, 2026, estimated value $40,000) supplying four injectable medications to Tampa Fire Rescue with a one-year contract term and SLBE 5 percent bid discount; the Texas Health and Human Services Commission's RFI (HHS0017013, posted April 3, 2026) gathering vendor capabilities for direct manufacturer prescription programs; and MMCAP's RFP (S1070000015802, due March 26, 2026) for generic multi-source pharmaceuticals distributed through three authorized wholesalers to state and local government facilities, with a two-year contract term and vendor participation across multiple participating states.